ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0273

Effector CD8+ T cells and PD-1hi CXCL13hi CD4+ T cells contribute to recurrent immune checkpoint inhibitor mediated inflammatory arthritis

Synat Keam1, Yuanteng Li2, Yanshuo Chu1, Jean Tayar3, Huifang Lu4, Michael Wu5, Sandeep Agarwal6, Nitin Jain7, Pavlos Msaouel1, Adi Diab2, Cara Haymaker1, Linghua Wang1, Roza Nurieva8 and Sang Kim9, 1The University of Texas MD Anderson Cancer Center, houston, 2MD Anderson Cancer Center, Houston, TX, 3The University of Texas, MD Anderson Cancer Center, Houston, TX, 4UT MD Anderson Cancer Center, Houston, TX, 5Baylor College of Medicine, Houston, 6Baylor College of Medicine, Houston, TX, 7The Universty of Texas MD Anderson Cancer Center, Houston, 8University of Texas MD Anderson, Houston, TX, 9Yale University, Branford, CT

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Immune checkpoint inhibitor (ICI) therapy is associated with life- and/or organ-threatening immune-related adverse events, including inflammatory arthritis (ICI-IA). However, the mechanisms behind ICI-IA, especially when it recurs, have not been fully elucidated. Thus, longitudinal sample analyses provide valuable information to understand disease pathogenesis. The purpose of the study is to elucidate mechanisms of ICI-IA by analyzing longitudinal synovial fluid (SF) samples.

Methods: SF samples were collected from six ICI-IA patients at the first and second occurrences of the IA flare and analyzed with single-cell RNA sequencing (scRNAseq), scTCRseq, scBCRseq, and flow cytometry. SF samples from cancer-naïve osteoarthritis (OA) patients were used as negative controls.

Results: SF effector CD8+ T cells and PD-1hi CXCL13hi CD4+ T cells were clonally expanded, implying their role in ICI-IA pathogenesis. Ninety three % of the top 10 expanded effector CD8+ T cell clones were shared between the first and second ICI-IA flare, with 47% of them are being expanded in the second IA flare. For PD-1hi CXCL13hi CD4+ T cells, half of the top 10 clones were shared between first and second ICI-IA flares, and 60% of shared clones were expanded in the second IA flare. Effector CD8+ T cells and PD-1hi CXCL13hi CD4+ T cells produced inflammatory cytokines including IFNg, TNFa, and IL-21, especially in the second ICI-IA. Trajectory inference analysis demonstrated that effector CD8+ T cells were positioned after tissue-resident memory T cells and effector memory T cells. The trajectory within the CD4+ T cells indicated that recently activated CD4+ T cells have the developmental potential to become PD-1hi CXCL13hi CD4+ T cells. Effector CD8+ T cells and PD-1hi CXCL13hi CD4+ T cells interact with each other and with myeloid immune cells via chemokines (CXCL9/10/11/13, CCL5) and cytokines (MIF, IL-2/7/15/21). Age-associated B cells, B cell population expanded in autoimmune diseases, were seen expanded in the second ICI-IA flare.

Conclusion: Effector CD8+ T cells and PD-1hi CXCL13hi CD4+ T cells play a pivotal role in ICI-IA disease pathogenesis. These cells were more clonally expanded and produced more inflammatory cytokines in the second ICI-IA flare, implying immune memory responses. Understanding of these cells will shed light on therapeutic targets for ICI-IA and biomarkers to predict development or recurrence of ICI-IA, an emerging disease entity in rheumatology and oncology.  


Disclosures: S. Keam: None; Y. Li: None; Y. Chu: None; J. Tayar: None; H. Lu: None; M. Wu: None; S. Agarwal: None; N. Jain: None; P. Msaouel: None; A. Diab: None; C. Haymaker: None; L. Wang: None; R. Nurieva: None; S. Kim: None.

To cite this abstract in AMA style:

Keam S, Li Y, Chu Y, Tayar J, Lu H, Wu M, Agarwal S, Jain N, Msaouel P, Diab A, Haymaker C, Wang L, Nurieva R, Kim S. Effector CD8+ T cells and PD-1hi CXCL13hi CD4+ T cells contribute to recurrent immune checkpoint inhibitor mediated inflammatory arthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/effector-cd8-t-cells-and-pd-1hi-cxcl13hi-cd4-t-cells-contribute-to-recurrent-immune-checkpoint-inhibitor-mediated-inflammatory-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effector-cd8-t-cells-and-pd-1hi-cxcl13hi-cd4-t-cells-contribute-to-recurrent-immune-checkpoint-inhibitor-mediated-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology